Unsymmetrical Pyrrolobenzodiazepine Dimers for DNA Lesion Formation

The patent applies asymmetry by introducing different aryl substituents at the C2 position of each PBD monomer unit in the dimer structure. Specifically, one monomer has an aryl group with a specific substituent pattern while the other monomer has a different aryl group substituent pattern, creating an unsymmetrical dimeric PBD compound. This asymmetric substitution strategy increases structural diversity and versatility while maintaining the core dimeric framework that enables straightforward synthesis through established coupling methods.

The patent applies local quality by introducing functionally distinct aryl substituents at specific C2 positions of each PBD monomer. Each aryl group is designed with specific substituent patterns (e.g., different positions and types of substituents on the aryl rings) that confer different biological activities and cytotoxic profiles. This localized differentiation allows the dimer to exhibit enhanced therapeutic versatility and expanded cytotoxic activity range while maintaining manufacturing simplicity through the use of standard coupling chemistry at the C8/C'-hydroxyl functionalities.

The patent applies segmentation by developing a modular synthesis approach where the unsymmetrical dimeric PBD compound is constructed from two independently prepared PBD monomer units, each bearing different aryl substituents at the C2 position. The monomers are synthesized separately using established routes, allowing for optimization of each fragment independently, and then coupled together through their C8/C'-hydroxyl functionalities. This segmented strategy enables structural diversity through varied aryl substitution while managing synthesis complexity through the use of standardized coupling chemistry and discrete monomer preparation steps.